SBH
ANIK icon

Segall Bryant & Hamill’s Anika Therapeutics ANIK Stock Holding History

Segall Bryant & Hamill’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-108,799
Closed -$2.69M – 579
2024
Q3 		$2.69M Buy
108,799
+1,794
+2% +$46.5K 0.04% 402
2024
Q2 		$2.71M Buy
+107,005
New +$2.77M 0.05% 353

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Segall Bryant & Hamill's ANIK Position: Q4 2024 in Review

Segall Bryant & Hamill sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 108,799 shares — an estimated $2.69M sold.

Segall Bryant & Hamill first reported a position in ANIK in Q2 2024 and held it in 2 quarters. The position peaked at $2.71M in Q2 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Segall Bryant & Hamill reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Segall Bryant & Hamill sold 108,799 Anika Therapeutics shares in Q4 2024, an estimated $2.69M.
  • Segall Bryant & Hamill first reported a position in Anika Therapeutics in Q2 2024 and held it in 2 quarters.
  • Segall Bryant & Hamill's Anika Therapeutics position peaked at $2.71M in Q2 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Segall Bryant & Hamill's 13F filing for Q4 2024, filed 11 Feb 2025.